Cabergoline
- Generic Name
- Cabergoline
- Brand Names
- Dostinex
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37N5O2
- CAS Number
- 81409-90-7
- Unique Ingredient Identifier
- LL60K9J05T
- Background
Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.
- Indication
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
- Associated Conditions
- Hyperprolactinemia, Idiopathic hyperprolactinemic disorder
- Associated Therapies
- Inhibition of physiological lactation
A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 36
- Registration Number
- NCT06909123
Non-surgical Interventions for Infertility in Endometriosis
- Conditions
- Infertility, FemaleEndometriosis
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Target Recruit Count
- 18
- Registration Number
- NCT06560814
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
- Conditions
- Lactation SuppressedSecond Trimester Abortion
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 200
- Registration Number
- NCT06123026
- Locations
- 🇺🇸
Northwestern Medical Center, Chicago, Illinois, United States
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 72
- Registration Number
- NCT06029673
- Locations
- 🇺🇸
Planned Parenthood - San Jose Central Health Center, San Jose, California, United States
🇺🇸Stanford University, Stanford, California, United States
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Al-Rasheed University College
- Target Recruit Count
- 75
- Registration Number
- NCT05981742
- Locations
- 🇮🇶
Maternity and Pediatric Teaching Hospital, Al Qādisīyah, Al-Qādisiyyah Governorate, Iraq
Cabergoline as a Preventive Treatment for Chronic Migraine
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 36
- Registration Number
- NCT05525611
- Locations
- 🇩🇰
Medical Research Laboratory, Department of Clinical Medicine, Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus N, Region Midtjylland, Denmark
Lactation Inhibition, the Efficiency of Vitamin B6 Versus Cabergoline
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 89
- Registration Number
- NCT05024422
- Locations
- 🇮🇱
HaEmek Medical Center, Afula, Israel
Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 73
- Registration Number
- NCT04701333
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia.
- Conditions
- Health Education
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Woman's Health University Hospital, Egypt
- Target Recruit Count
- 120
- Registration Number
- NCT04262024
- Locations
- 🇪🇬
Woman's Health University Hospital, Assiut, Egypt
Cabergoline Before or After Oocyte Collection for Follicular Resolution
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Fertility Center of Las Vegas
- Target Recruit Count
- 70
- Registration Number
- NCT04096027
- Locations
- 🇺🇸
Fertility Center of Las vegas, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.